This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology  • Lung Cancer  • Pulmonary Diseases, Other  • Computed Tomography  • Drug Therapy, Other  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2008;300(3):267-268.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chicago—With lung cancer claiming the lives of more men and women than colon, breast, and prostate cancers combined, the need for agents to prevent this malignancy has never been more urgent. Although efforts have been unsuccessful to date, preliminary research reported here at the recent Annual Meeting of the American Society of Clinical Oncology suggests that drugs that inhibit the cyclooxygenase 2 (COX-2) enzyme may have potential as chemoprevention agents.

Other presentations at the meeting highlighted a new imaging protocol that may help clinicians determine which patients with lung cancer might benefit from surgery and a combination treatment that appears to offer a small improvement in survival.

Recently reported clinical trials assessed new and potentially promising options for preventing, imaging, and treating lung cancer. (Photo credit: Creative Living Art Enterprises, LLC/www.sciencesource.com)

PREVENTION FROM A PAIN RELIEVER

COX-2 inhibitors such as celecoxib, valdecoxib, and rofecoxib have made headlines in recent . . . [Full Text of this Article]